I’m still waiting on molecular and DNA results, but so far we know my son has Astrocytoma with an IDH mutation,...

I'm so glad you're reaching out—this is a lot to process, and I want to help you understand what you're dealing with and what comes next.

What You're Looking At: Grade 2 vs. Grade 3 Astrocytoma

The grade matters significantly because it determines how aggressively the tumor grows and what treatment approach your son's team will recommend.

According to the NCCN Guidelines for Patients: Glioma, here's what distinguishes these grades:

Grade 2 Astrocytoma:

• Tumor cells look somewhat abnormal under the microscope
• Grows slowly and can invade normal brain tissue
• May not grow back for many years
• When it does recur, it often comes back as a higher grade

Grade 3 Astrocytoma:

• Tumor cells look very different from normal cells
• Grows and spreads more quickly
• Requires additional therapy (radiation + chemotherapy) after surgery
• More aggressive behavior overall

The final pathology report will clarify which category your son falls into—this is crucial information for treatment planning.

---

The Good News About the IDH Mutation

This is actually an important positive finding. According to NCCN Guidelines, an IDH mutation in a high-grade astrocytoma generally indicates longer survival and a better outcome from radiation therapy or chemotherapy compared to astrocytomas without this mutation.

Think of it this way: the IDH mutation is a genetic marker that helps predict how the tumor will respond to treatment—and the prognosis tends to be more favorable.

---

What the Pending Molecular Tests Will Tell You

The additional biomarker testing your team is doing will likely include:

ATRX mutation – When found along with an IDH mutation, this helps confirm the astrocytoma diagnosis and provides more information about prognosis.

MGMT promoter methylation – This is particularly important because:

• If the MGMT promoter is methylated (a specific chemical change), temozolomide chemotherapy generally works better and leads to longer survival
• If it's unmethylated, your team may adjust the treatment approach
• This biomarker helps personalize which chemotherapy drugs will be most effective

These tests refine the diagnosis and help your son's oncology team choose the most targeted treatment approach.

---

What Typically Happens Next (Treatment Overview)

According to NCCN Guidelines, the standard approach for high-grade astrocytoma is:

Step 1: Surgery (if not already done)

• Goal: safely remove as much tumor as possible (called "maximal safe resection")
• Because astrocytomas invade surrounding brain tissue, removing the entire tumor usually isn't possible

Step 2: Additional Treatment (Adjuvant Therapy) For a younger patient with good overall health, typical options include:

• Radiation therapy + Temozolomide chemotherapy given together, followed by more temozolomide
• Radiation therapy followed by temozolomide chemotherapy
• Clinical trial participation (NCCN experts strongly recommend considering this)

The specific recommendation will depend on:

• Your son's age and overall health
• The final grade determination
• The complete biomarker panel results
• His performance status (ability to tolerate treatment)

---

Critical Questions to Ask Your Oncology Team NOW

While you're waiting for the molecular results, prepare these questions:

About the diagnosis:

1. Once the final grade is determined, what does that mean for treatment intensity?
2. How do the IDH mutation and other biomarkers affect my son's prognosis and treatment options?
3. What does the MGMT methylation status mean for chemotherapy selection?

About treatment planning: 4. Will my son need additional surgery, or has the tumor been fully resected? 5. What is the recommended adjuvant treatment plan for his specific situation? 6. Are there clinical trials available that might be appropriate for him?

About side effects and quality of life: 7. What are the most common side effects of the recommended treatment, and how will they be managed? 8. How will treatment affect his daily life, school, activities? 9. What rehabilitation or supportive services are available (speech therapy, occupational therapy, neuropsychological support)?

About follow-up: 10. What will follow-up monitoring look like after treatment? 11. How often will he need MRI scans, and what are we looking for?

---

What You Should Do Right Now

1. Get copies of all pathology reports – Ask for the complete neuropathology report with all biomarker results once they're available

2. Request a multidisciplinary team meeting – According to NCCN Guidelines, your son's care should involve doctors, specialists, and other health providers working as a team. This typically includes:

   • Neuro-oncologist (brain cancer specialist)
   • Neurosurgeon
   • Radiation oncologist
   • Possibly others

3. Ask about clinical trials – NCCN experts specifically recommend that anyone with a high-grade glioma consider clinical trial participation. Ask your team:

   • What trials are available for his specific diagnosis?
   • How do you find trials? (ClinicalTrials.gov is a good resource)

4. Connect with support resources – This is a marathon, not a sprint:

   • Ask about support groups (brain tumor-specific if possible)
   • Inquire about social work/patient navigator services
   • Ask about financial assistance programs

5. Keep detailed records – Document symptoms, side effects, scan results, and treatment dates. This helps your team track progress and adjust care as needed.

---

Important Context: Age Matters

Your son's age will significantly influence treatment recommendations. Younger patients with good overall health can typically tolerate more intensive treatment (radiation + chemotherapy together), while older or frailer patients may receive less intense therapy to minimize side effects while still being effective.

Make sure your team knows his complete health picture so they can tailor recommendations appropriately.

---

Next Steps: When You Get the Molecular Results

Once the complete biomarker panel comes back, you'll have:

• Definitive grade (2 or 3)
• ATRX status
• MGMT methylation status
• Any other relevant mutations

This is when you'll have the clearest picture of what treatment will look like and what to expect. Don't hesitate to ask your team to explain how each result influences the treatment plan.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

I'm here to help you understand the medical information as it comes in. Feel free to share the molecular results when you get them, and I can help you understand what they mean and what questions to ask next.